Butterfly Network (BFLY) Q3 2023: Software Mix Jumps to 43% as Platform Pivot Gains Traction
Butterfly Network’s platform shift accelerated in Q3, with software and services now 43% of revenue, up 10 points YoY. The company is executing a multi-pronged transformation, balancing cost discipline with investment in next-gen hardware, AI partnerships, and education to reignite growth in 2024. Management’s focus on recurring revenue and ecosystem expansion positions Butterfly for a return to double-digit growth as IQ3 launches and new verticals open.
Summary
- Recurring Revenue Mix Surges: Software and services now comprise nearly half the business, underscoring the pivot to platform economics.
- AI Ecosystem and Education Initiatives Accelerate: Butterfly Garden and ScanLab drive adoption and partner engagement.
- 2024 Growth Engine Primed: IQ3 launch and international momentum set the stage for a double-digit revenue rebound.
Business Overview
Butterfly Network develops and sells handheld, semiconductor-based ultrasound devices and supporting software for point-of-care imaging. The core business spans hardware sales, subscription-based software, and professional services, serving clinicians and institutions globally. The company’s platform strategy leverages its proprietary chip technology, enabling recurring revenue from software, AI tools, and ecosystem partnerships, with major segments including product sales, software subscriptions, and enterprise solutions.
Performance Analysis
Q3 reflected the full impact of Butterfly’s transition from hardware-centric sales to a software-driven platform model. While total revenue declined year over year, this was largely attributable to the absence of two outsized deals in 2022 (Gates and Rochester), which created a tough comparison. Excluding these, the underlying U.S. and international businesses were flat, signaling stabilization in core demand.
Software and services revenue grew 3% YoY and now represents 43% of total revenue, up from 33% a year ago. This shift was driven by a larger installed base, higher renewal rates, and increased enterprise software uptake, with annual recurring revenue (ARR) up 19% and enterprise ARR up 51%. Gross margin improved to 61%, reflecting the higher mix of software and efficiency gains, despite lower product volumes. Adjusted EBITDA loss narrowed sharply, benefiting from a $170 million reduction in operating costs over the past year.
- Product Volume Headwind: Hardware sales fell due to non-recurring prior-year deals, but average selling prices increased.
- Subscription and Enterprise Upsell: Growth in recurring software revenue and enterprise penetration offset some hardware softness.
- Cost Structure Reset: Operating expenses and cash burn declined significantly, extending runway into 2026.
Despite top-line pressure, the business model is shifting toward higher-margin, recurring software and ecosystem revenue streams.
Executive Commentary
"Butterfly Network is a great technology platform with leading products and services. We're now focused on not only providing the best point of care ultrasound solutions, but also expanding our addressable market through adjacencies to return the company to organic growth."
Joseph DeVito, Chairman and Chief Executive Officer
"Our total annual recurring revenue, which is reported as part of software and other services, grew by 19%. This was led by a strong increase of 51% in our enterprise software, which increased from 31% to 40% of our total ARR."
Heather Goetz, Chief Financial and Operations Officer
Strategic Positioning
1. Platform and Ecosystem Expansion
Butterfly is evolving from a device company to an integrated platform, leveraging its proprietary semiconductor chip to build a recurring revenue base. The Butterfly Garden initiative opens the platform to external AI developers, with over 100 partner inquiries and multiple university and commercial signings, monetized via annual SDK fees and revenue share on app sales.
2. Next-Gen Hardware and AI Differentiation
The upcoming IQ3 device marks a step-change in image quality and processing power, with performance now rivaling or exceeding analog competitors. This leap is designed to overcome historical barriers to adoption and expand addressable markets, especially in cardiac and specialty imaging, setting the stage for broader enterprise wins.
3. Education and Adoption Initiatives
Educational offerings like Butterfly Academy, ScanLab, and Butterfly Certified are central to accelerating user proficiency and driving probe and software adoption. ScanLab, an AI-powered training app, is expected to lower onboarding friction and support medical school and enterprise penetration, addressing the “ultrasound paradox” of accessibility versus usability.
4. International and Enterprise Growth
International markets are expected to return to growth ahead of the U.S., as distributor inventory normalizes and new sales leadership activates expansion. Enterprise software growth is robust, and the sales force has been rebuilt after prior-year restructuring, positioning the company to capture larger, system-level deals.
5. Leverage of Core Technology in New Verticals
Powered by Butterfly partnerships, like the Forrest Neurotech brain-computer interface project, demonstrate the company’s ability to monetize its chip technology in adjacent, non-competitive markets, creating additional royalty and revenue streams without incremental R&D burden.
Key Considerations
This quarter underscores Butterfly’s commitment to a recurring, software-centric model, while also investing in the next wave of hardware and ecosystem expansion.
Key Considerations:
- Recurring Revenue Momentum: The shift to software and services is raising gross margins and lowering volatility, but requires continued execution to offset hardware cyclicality.
- AI Marketplace Potential: Butterfly Garden could become a leading ultrasound AI platform, but user adoption and partner app traction are early-stage risks.
- IQ3 Launch Execution: The timing and uptake of IQ3, pending FDA approval, will be critical to reaccelerating growth and enterprise penetration.
- International Recovery: Distributor and inventory normalization is expected to drive earlier growth abroad, but macro and regulatory factors remain variables.
- Cost Discipline Sustainability: Operating cost reductions have extended runway, but further margin expansion will depend on scaling high-margin software and services.
Risks
Butterfly faces execution risk around the IQ3 launch, including potential delays in FDA approval and customer adoption lag due to the Osborne effect, where buyers delay purchases ahead of new product release. International recovery is subject to distributor performance and macro factors, while the success of Butterfly Garden and Powered by Butterfly partnerships is unproven and dependent on ecosystem adoption. Competitive pressure from analog and emerging digital rivals persists, particularly as larger players invest in chip-based and AI-enabled ultrasound.
Forward Outlook
For Q4 and into 2024, Butterfly guided to:
- Full year 2023 revenue of at least $64 million (unchanged)
- Improved adjusted EBITDA loss of $70-$75 million for the year (tightened by $5 million)
Management expects:
- Return to double-digit revenue growth in 2024, driven by IQ3, software, and international acceleration
- International growth to outpace domestic in early 2024, with U.S. recovery ramping post-IQ3 launch
- Continued cash runway into 2026, with further efficiency gains and margin improvement
Takeaways
- Platform Shift in Motion: Butterfly is successfully transitioning to a higher-margin, recurring revenue model, with software and services now 43% of revenue and ARR growth outpacing hardware.
- Execution on Multiple Fronts: New product launches, education initiatives, and AI ecosystem expansion are laying the foundation for a return to growth, but near-term results remain pressured by hardware headwinds and product cycle timing.
- 2024 Inflection Point: Investors should watch for IQ3 FDA approval, Butterfly Garden partner traction, and international sales momentum as leading indicators of the platform’s scalability and competitive positioning.
Conclusion
Butterfly Network’s Q3 results reflect a business in strategic transition, with clear progress on recurring revenue, cost discipline, and platform expansion. The coming year will test the company’s ability to turn product and ecosystem investments into sustained, profitable growth, with the IQ3 launch and AI marketplace as key catalysts.
Industry Read-Through
Butterfly’s results signal a broader industry pivot from hardware-led to platform-enabled ultrasound solutions, where recurring software and AI ecosystem revenue are becoming critical to margin and growth. The rapid expansion of AI partnerships and educational offerings highlights the need for user enablement and workflow integration as adoption hurdles. Competitors investing in digital and chip-based ultrasound must accelerate their own ecosystem and software strategies, or risk being outflanked by more agile, platform-centric models. For medtech investors, the trajectory of recurring revenue and partner engagement is emerging as a key valuation driver across the sector.